Department of Neurology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Am J Manag Care. 2011 May;17 Suppl 5 Improving:S154-60.
Multiple sclerosis (MS) is a complex chronic, progressing disease that contributes to poor quality of life (QOL) for patients and high costs for managed care organizations. Currently, disease-modifying treatments (DMTs) constitute the platform pharmacotherapy for MS patients. Despite their efficacy, for many patients taking DMTs there is little evidence of their effect on QOL in general or symptom management. Impaired mobility contributes to direct and indirect costs. Annual direct medical costs for MS with gait impairment average nearly $21,000 per patient. Decreased mobility is also associated with higher absenteeism rates, thus raising indirect costs. Dalfampridine has been shown to improve walking in patients with MS. The effects of dalfampridine can complement those of DMTs by improving walking ability as a key component of overall mobility and a primary concern among many MS patients. Improved walking could potentially help contain some of the direct and indirect costs associated with MS care.
多发性硬化症（MS）是一种复杂的慢性进行性疾病，会降低患者的生活质量（QOL）并增加管理式医疗保健组织的成本。目前，疾病修正治疗（DMT）是 MS 患者的基础药物治疗。尽管这些治疗药物有效，但对于许多接受 DMT 的患者来说，它们对 QOL 或症状管理的影响证据有限。行动能力受损会导致直接和间接成本增加。步态障碍 MS 的年直接医疗费用平均每位患者近 21,000 美元。行动能力下降也与更高的旷工率相关，从而增加了间接成本。达非那新已被证明可改善 MS 患者的行走能力。达非那新的作用可以通过改善行走能力来补充 DMT 的作用，行走能力是整体活动能力的关键组成部分，也是许多 MS 患者主要关注的问题。改善行走能力可能有助于控制与 MS 护理相关的部分直接和间接成本。
